A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver

Summary

The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the patterns of failure and survival. The primary response measurements will be the achievement of an objective tumor response, response duration and progression-free survival

Timeline

Start

2004-09

Primary completion

2010-04

Completion

2010-04

Outcome

Outcome not reported

Stopped (Enrollment): “recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated”

Drugs

Indications